D-环丝氨酸增强暴露疗法治疗强迫症。
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.
作者信息
Kushner Matt G, Kim Suck Won, Donahue Christopher, Thuras Paul, Adson David, Kotlyar Michael, McCabe James, Peterson Jillian, Foa Edna B
机构信息
Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota 55454, USA.
出版信息
Biol Psychiatry. 2007 Oct 15;62(8):835-8. doi: 10.1016/j.biopsych.2006.12.020. Epub 2007 Jun 22.
BACKGROUND
D-cycloserine (DCS), a glutamatergic partial N-methyl-d-aspartate (NMDA) agonist, can facilitate extinction learning related to cued fear in animals and humans. We predicted that DCS would accelerate obsession-related distress reduction in patients with obsessive-compulsive disorder (OCD) undergoing extinction-based exposure therapy.
METHODS
We administered DCS (125 mg) or placebo in a double-blind fashion to individuals with OCD approximately 2 hours before each exposure session.
RESULTS
D-cycloserine decreased both the number of exposure sessions required to achieve clinical milestones and the rate of therapy dropout. After four exposure sessions, patients in the DCS group reported significantly greater decreases in obsession-related distress compared with the placebo group; however, after additional sessions, the placebo group tended to catch up.
CONCLUSIONS
D-cycloserine augmentation has the potential to increase the efficiency, palatability, and overall effectiveness of standard exposure therapy for OCD.
背景
D-环丝氨酸（DCS）是一种谷氨酸能部分N-甲基-D-天冬氨酸（NMDA）激动剂，可促进动物和人类与线索性恐惧相关的消退学习。我们预测，DCS将加速接受基于消退的暴露疗法的强迫症（OCD）患者与强迫观念相关的痛苦减轻。
方法
在每次暴露治疗前约2小时，我们以双盲方式给患有强迫症的个体服用DCS（125毫克）或安慰剂。
结果
D-环丝氨酸减少了达到临床里程碑所需的暴露治疗次数以及治疗退出率。经过四次暴露治疗后，与安慰剂组相比，DCS组患者报告与强迫观念相关的痛苦显著减轻；然而，在额外的治疗后，安慰剂组倾向于赶上。
结论
D-环丝氨酸增强疗法有可能提高强迫症标准暴露疗法的效率、可接受性和总体有效性。
Zotero 插件